Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
586
datasets available to search
ShareScore release 0.9.0
Dataset results
586 results for “allogeneic stem cell transplant”
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
ClinicalTrials.gov study NCT03657160. IPD Sharing: YES. Countries: 27. Publications: 1.
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
ClinicalTrials.gov study NCT03774082. IPD Sharing: YES. Countries: 14. Publications: 1.
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
ClinicalTrials.gov study NCT02913261. IPD Sharing: YES. Countries: 22. Publications: 5.
A longitudinal study of DNA and RNA viruses plasma detection in allogeneic hematopoietic stem cell transplant recipients
<p><span><strong>Background:</strong> </span><span>Viral infections are among the most common complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and can be associated with transient or sustained viremia. Besides viruses that are common causes of infection, metagenomics revealed the presence of several novel viruses and variants that are overlooked in clinical routine and represent potential sources of unrecognized systemic infections</span><span>. Our aim was to describe the prevalence and the dynamics of 17 DNA and 3 RNA viral infections using (r(RT-)PCR) assays on plasma samples of adult allo-HSCT recipients over a one-year period after HSCT.</span></p> <p><strong><span>Methods:</span></strong><span> 109 adult patients that received a first allo-HSCT from 1<sup>st</sup> March 2017 to 31<sup>st</sup> January 2019 we included in this</span> <span>longitudinal observational monocentric cohort study</span><span>.</span> <span>17 DNA and 3 RNA viral species were screened with qualitative and/or quantitative r(RT)-PCR assays performed on plasma samples </span><span>collected at five time-points (day 0 and 30 days, 3 months, 6 months and one year after HSCT). </span></p> <p><strong><span>Results: </span></strong><span>TTV was the most prevalent with an increasing prevalence to 96% of patients at 3 months. HPgV-1 prevalence ranged from 26 to 36% of patients. TTV and HPgV-1 plasma viral load peaked at month 3 (TTV: median 3.29E5 copies/ml [range, 3.37E2 to 4.06E9 copies/ml]; HPgV-1: median 1.18E6 copies/ml [range, 2.61E3 to 4.49E7 copies/ml]). Among <em>Polyomaviridae</em>, BKPyV, JCPyV, MCPyV, HPyV6 and 7 were detected in ≥10% of patients at ≥1 time-point. HPyV6 and HPyV7 prevalence reached 27% and 12% of patients at month 3. Among those, 41% and 63% had quantifiable viral loads, with median viral loads above 1E3copies/ml and results may suggest HPyV6 sustained viremia. Co-detections were frequent, in particular at 3 months with ≥2 viruses detected in 72% of patients. </span></p> <p><strong><span>Conclusion: </span></strong><span>Our study confirms that TTV and HPgV-1 infections are highly prevalent and that infection may be sustained up to one year after allo-HSCT. Our systematic and large strategy of screening also revealed diverse and numerous co-detections, and that several novel <em>Polyomaviridae</em> (MCPyV, HPyV6/7) that are overlooked in clinical routine are as or more frequently detected compared to classical culprits. Our results underscores the need for further studies investigating the clinical impact of classical culprits together with other viruses in particular novel <em>Polyomaviridae</em> and HPgV-1. </span></p>
Rational Modification of Human Gut Microbial Metabolites by Dietary Resistant Starch in Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Feasibility Study
<p>We conducted a prospective longitudinal feasibility study in patients undergoing allo-HCT for hematological malignancies to test the hypothesis that defined and consistent administration of resistant starch will rationally modify intestinal microbiota dependent metabolites, particularly the short chain fatty acids (SCFA), such as butyrate. Ten adults undergoing human leukocyte antigen-matched, related-donor myeloablative allo-HCT were enrolled and received resistant potato starch (RPS) daily from day -7 to day 100 after allo-HCT. </p>
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
ClinicalTrials.gov study NCT02981914. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
ClinicalTrials.gov study NCT03565900. IPD Sharing: YES. Countries: 10. Publications: 1.
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7
ClinicalTrials.gov study NCT02663622. IPD Sharing: YES. Countries: 1. Publications: 4.
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
ClinicalTrials.gov study NCT00153985. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
ClinicalTrials.gov study NCT01131169. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
ClinicalTrials.gov study NCT01427881. IPD Sharing: Not stated. Countries: 1. Publications: 1.
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT03263442. IPD Sharing: NO. Countries: 1. Publications: 1.
Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
ClinicalTrials.gov study NCT03940586. IPD Sharing: YES. Countries: 11. Publications: 2.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
ClinicalTrials.gov study NCT00369226. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT02338232. IPD Sharing: Not stated. Countries: 1. Publications: 108.
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With L
ClinicalTrials.gov study NCT00928018. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Sy
ClinicalTrials.gov study NCT01835587. IPD Sharing: Not stated. Countries: 2. Publications: 1.
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov study NCT04014790. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
ClinicalTrials.gov study NCT00141726. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
ClinicalTrials.gov study NCT00859586. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.